
|Articles|February 24, 2010
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
4
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
5


















